Rapamycin may prevent post-transplant lymphoma.
Garber
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology / Q000517:prevention & control*; D051379:Mice; D009362:Neoplasm Metastasis; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D020123:Sirolimus / Q000627:therapeutic use*; D014181:Transplantation Immunology; D014412:Tumor Virus Infections / Q000150:complications / Q000276:immunology; D014775:Virus Activation
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D020123:Sirolimus